Circular RNA vaccines against SARS-CoV-2 and emerging variants
Liang Qu,Zongyi Yi,Yong Shen,Liangru Lin,Feng Chen,Yiyuan Xu,Zeguang Wu,Huixian Tang,Xiaoxue Zhang,Feng Tian,Chunhui Wang,Xia Xiao,Xiaojing Dong,Li Guo,Shuaiyao Lu,Chengyun Yang,Cong Tang,Yun Yang,Wenhai Yu,Junbin Wang,Yanan Zhou,Qing Huang,Ayijiang Yisimayi,Shuo Liu,Weijin Huang,Yunlong Cao,Youchun Wang,Zhuo Zhou,Xiaozhong Peng,Jianwei Wang,Xiaoliang Sunney Xie,Wensheng Wei
DOI: https://doi.org/10.1016/j.cell.2022.03.044
IF: 64.5
2022-04-01
Cell
Abstract:As the emerging variants of SARS-CoV-2 continue to drive the worldwide pandemic, there is a constant demand for vaccines that offer more effective and broad-spectrum protection. Here, we report a circular RNA (circRNA) vaccine that elicited potent neutralizing antibodies and T cell responses by expressing the trimeric RBD of the spike protein, providing robust protection against SARS-CoV-2 in both mice and rhesus macaques. Notably, the circRNA vaccine enabled higher and more durable antigen production than the 1mΨ-modified mRNA vaccine and elicited a higher proportion of neutralizing antibodies and distinct Th1-skewed immune responses. Importantly, we found that the circRNARBD-Omicron vaccine induced effective neutralizing antibodies against the Omicron but not the Delta variant. In contrast, the circRNARBD-Delta vaccine protected against both Delta and Omicron or functioned as a booster after two doses of either native- or Delta-specific vaccination, making it a favorable choice against the current variants of concern (VOCs) of SARS-CoV-2.
cell biology,biochemistry & molecular biology